Immune booster shot before breast surgery shows promise in early trial
NCT ID NCT07319195
First seen Jan 10, 2026 · Last updated May 02, 2026 · Updated 18 times
Summary
This early-phase trial tests whether giving an immune-boosting drug (Mitazalimab) alone or with another drug (Nivolumab) directly into the tumor before surgery is safe and helps the immune system fight breast cancer. About 32 adults with early-stage or recurrent breast cancer that can be removed by surgery will receive one injection 7 or more days before their operation. The study focuses on safety, whether surgery is delayed, and how the immune system responds.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.